Novartis lifts sales outlook despite Q2 profit dip

July 17, 2013 by John Heilprin
This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical company Novartis AG on one of their buildings in Basel, Switzerland. Swiss pharmaceutical company Novartis AG raised its sales outlook for the full year on Wednesday July 17, 2013 , despite posting a 5 percent net income drop in the second quarter. The Basel-based company said it expects full-year sales to grow at a rate in the low single-digits, boosted by delays in generic competition against its blockbuster Diovan. In April, the company had said in its first-quarter results that it expected sales to be in line with last year's. (AP Photo/Keystone, Georgios Kefalas, File).

(AP)—Swiss pharmaceutical company Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter.

The Basel-based company said it expects full-year sales to grow at a rate in the low single-digits, boosted by delays in generic competition against its blockbuster Diovan. In April, the company said in its first-quarter results that it expected sales to be in line with last years.

Diovan, which is generically known as Valsartan, is a treatment for high blood pressure which lost U.S. patent protection last year. Novartis has been counting on new product launches, such as Gilenya for multiple sclerosis and Afinitor for cancer, to offset patent expirations. A key one is blockbuster leukemia drug Gleevec, which is to begin losing U.S. patent protection in 2015.

Meantime, the company's board of directors announced that its outgoing board chairman, Daniel Vasella, would receive $5.2 million in cash and unrestricted shares plus a guaranteed minimum fee of $250,000 a year from 2014 through 2016, just to be available for consulting and coaching. He'll be paid a consulting rate of $25,000 a day.

Vasella's departure touched off widespread anger in Switzerland—and led to a national debate over executives' pay—for the huge $77 million severance package he was offered. He later declined to accept it because of the Swiss public's outcry.

Shares in Novartis closed down 0.43 percent at 68.80 Swiss francs on the Zurich exchange Wednesday.

Novartis said in its financial results that quarterly net income fell to $2.548 billion, down from $2.675 billion in the comparable period a year ago. The company pointed to loss of patents, pricing pressure and the weakening Japanese yen as factors, though it said the currency impact "represents a larger proportion of operating income than sales."

Joseph Jimenez, CEO of Novartis, said the company delivered a solid second quarter, with sales of Gilenya a particular highlight.

"Despite having new competition in that space, Gilenya was up 66 percent versus a year ago," he told reporters. "There are many emerging markets where products that have already generic competition are still growing, because of the strength of those brands, and because of the high quality of those medicines."

Explore further: Novartis posts profit gain thanks to new drugs (Update)

Related Stories

Novartis posts profit gain thanks to new drugs (Update)

April 24, 2013
(AP)—Swiss pharmaceutical company Novartis AG reported a 6.7 percent increase in profit for the first quarter Wednesday, boosted by new products and emerging markets.

New drugs shore up Novartis in Q2

July 19, 2012
(AP) — Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines and the strengthening ...

Novartis chief sees sales dip until mid-2013

October 7, 2012
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Novartis Q4 net profit rebounds to $2.1 billion

January 23, 2013
(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.

Novartis announces 2,000 job losses, profits up

October 25, 2011
Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Sanofi earnings slashed in first quarter

May 2, 2013
(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.